Ernexa Therapeutics Inc. Business Acquisition, Pro Forma Net Income (Loss)
Ernexa Therapeutics Inc. (ERNA) reported Business Acquisition, Pro Forma Net Income (Loss) of -$122.56 million for the 12-month period ending 2021-12-31, per its 10-K/A filed 2022-07-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2022-07-01
- Ernexa Therapeutics Inc. business acquisition, pro forma net income (loss) for the quarter ending 2021-12-31 was -$8.71M.
- Ernexa Therapeutics Inc. business acquisition, pro forma net income (loss) for the quarter ending 2021-06-30 was -$27.80M.
- Ernexa Therapeutics Inc. business acquisition, pro forma net income (loss) for the quarter ending 2021-03-31 was -$17.70M.
- Ernexa Therapeutics Inc. business acquisition, pro forma net income (loss) for the quarter ending 2020-12-31 was -$2.23M.
- Ernexa Therapeutics Inc. business acquisition, pro forma net income (loss) for fiscal 2021 was -$122.56M.
- Ernexa Therapeutics Inc. business acquisition, pro forma net income (loss) for fiscal 2020 was -$7.31M.
- Ernexa Therapeutics Inc. business acquisition, pro forma net income (loss) for fiscal 2012 was -$995.00K.
- Ernexa Therapeutics Inc. business acquisition, pro forma net income (loss) for fiscal 2011 was -$3.51M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | -$8.71M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-01 | -$122.56M 10-K/A · filed 2022-07-01 | -$122.31M 10-K · filed 2022-04-15 | ||
| 2021-09-30 | -$113.85M 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | -$27.80M 10-Q · filed 2021-08-13 | -$45.50M derived: sum of 2 quarters · filed 2021-08-13 | -$47.72M derived: sum of 3 quarters · filed 2022-07-01 | ||
| 2021-03-31 | -$17.70M 10-Q · filed 2021-05-17 | -$19.93M derived: sum of 2 quarters · filed 2022-07-01 | |||
| 2020-12-31 | -$2.23M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-01 | -$7.31M 10-K/A · filed 2022-07-01 | -$26.55M 10-K · filed 2022-04-15 | ||
| 2020-09-30 | -$5.08M 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | -$3.06M 10-Q · filed 2021-08-13 | -$4.08M derived: sum of 2 quarters · filed 2021-08-13 | |||
| 2020-03-31 | -$1.02M 10-Q · filed 2021-05-17 | ||||
| 2012-12-31 | -$993.38K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | -$993.32K derived: sum of 2 quarters · filed 2013-03-29 | -$995.00K 10-K · filed 2013-03-29 | ||
| 2012-09-30 | $54.00 10-Q · filed 2012-11-09 | -$1.62K 10-Q · filed 2012-11-09 | |||
| 2011-12-31 | -$3.51M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | -$3.51M derived: sum of 2 quarters · filed 2013-03-29 | -$3.51M 10-K · filed 2013-03-29 | ||
| 2011-09-30 | -$806.00 10-Q · filed 2012-11-09 | -$2.42K 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |